Key Points:
• Early Stage Melanoma: Discussion on the standard of care for different stages, including the role of neoadjuvant immunotherapy.
• Adjuvant Therapy: Controversies and considerations for stage 2 and beyond, including the use of ctDNA as a predictive tool.
• Neoadjuvant Therapy: Insights into recent trials and the evolving landscape of neoadjuvant treatment for melanoma.
• Metastatic Stage: Exploration of treatment options, including immunotherapy combinations and BRAF MEK inhibitors.
• TILS Therapy: Overview of the recent approval of Tumor Infiltrating Lymphocytes (TILS) therapy for melanoma patients.
In this episode of the Oncology Brothers podcast, Dr. Allison Betof Warner from Stanford University joined the hosts, Drs. Rahul and Rohit Gosain, to discuss the current standard of care and recent advances in cutaneous melanoma treatment. The discussion covered various stages of melanoma, from early-stage to metastatic disease.
Dr. Warner emphasized the evolving landscape of stage 2 melanoma treatment, highlighting the controversy surrounding adjuvant therapy and the challenges in selecting appropriate patients for treatment. The conversation also delved into the role of neoadjuvant therapy in stage 3 melanoma, with a focus on the benefits of pembrolizumab and the importance of patient selection.
The hosts and Dr. Warner discussed the efficacy of different treatment options in metastatic melanoma, including immunotherapy combinations, BRAF and MEK inhibitors, and the recent approval of TILS therapy. They emphasized the significance of clinical trials in advancing melanoma treatment and the importance of partnering with specialized centers for complex therapies like TILS.
Overall, the episode provided a comprehensive overview of the current treatment landscape for melanoma, highlighting the importance of personalized treatment approaches and the need for ongoing research to improve patient outcomes.
